Yubo International Biotech Ltd (YBGJ)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Sales of products and services | - | - | - | - |
| Cost of goods and services sold | - | - | - | - |
| Gross profit | - | - | - | - |
| Other operating expenses | - | 42,252 | 87,415 | 138,519 |
| Other operating expenses | -29,032 | - | - | - |
| Occupancy | 49,723 | 174,624 | 175,646 | 109,289 |
| Employee compensation | 183,864 | 205,800 | 220,118 | 177,820 |
| Depreciation and amortization of property and equipment | 41,744 | 41,263 | 45,995 | 41,408 |
| Amortization of intangible assets | 3,400 | 3,360 | 3,590 | 3,400 |
| Total operating expenses | 249,699 | 467,299 | 532,764 | 470,436 |
| Income (loss) from operations | -249,699 | -467,299 | -532,764 | -470,436 |
| Loss on obsolete inventory | - | - | - | -127,895 |
| Interest income (expense) | - | -19 | - | - |
| Loss on obsolete inventory | - | - | -88,338 | - |
| Interest expense | 23 | - | 49 | 17 |
| Total other income (expenses) | -23 | -19 | -88,289 | -127,912 |
| Loss before provision for income tax | -249,722 | -467,318 | -621,053 | -598,348 |
| Provision for income tax | - | - | - | - |
| Net loss | -249,722 | -467,318 | - | - |
| Net loss attributable to non-controlling interest | -19,389 | -31,688 | -40,210 | -70,838 |
| Net loss attributable to common stockholders | -230,333 | -435,630 | -580,843 | -527,510 |
| Net income (loss) available to common stockholders, basic | - | - | -580,843 | -527,510 |
| Basic & diluted eps | - | - | - | - |
| Basic & diluted average shares | - | - | - | 119,820,790 |
| Net loss per share basic and diluted | - | - | -0.01 | - |
| Weighted average common shares outstanding basic and diluted | 119,820,790 | 119,820,790 | 119,820,790 | - |